- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 342
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer, Solid Tumor, Hematologic Malignancy
- Interventions
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Type 1 Diabetes
- Interventions
- GTT@Home
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HIV Infections, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression, Substance Abuse
- Interventions
- Twinrix, Enhanced treatment as usual
- Drug · Behavioral
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- West Los Angeles, California
- Conditions
- Colorectal Cancer
- Interventions
- Patient Navigation, Usual Care Control
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 45 Years to 915 Months
- Enrollment
- 527 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer Screening
- Interventions
- PSA flyer
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 74 Years · Male only
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- NSCLC
- Interventions
- ctDNA, tumor NGS
- Diagnostic Test
- Lead sponsor
- Lung Cancer Mutation Consortium
- Network
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Davis, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Breast Cancer, Liquid Biopsy, Early Detection
- Interventions
- Not listed
- Lead sponsor
- Syantra Inc.
- Industry
- Eligibility
- 30 Years to 75 Years · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • New York, New York
- Conditions
- Latent Tuberculosis, HIV Infections
- Interventions
- T-Spot.TB test
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- Healthy
- Interventions
- [13C]Pantoprazole
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Genetic Counseling, Shared Decision Making, Pregnancy, Genetic Testing, Prenatal Disorder
- Interventions
- Meaning of Screening, Genetic Counseling, Usual Care
- Behavioral
- Lead sponsor
- Erin Rothwell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,045 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Chapel Hill, North Carolina • Salt Lake City, Utah
- Conditions
- Cancer, Depression
- Interventions
- iPath*D
- Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Saint Johnsbury, Vermont
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma, Melanoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Month and older
- Enrollment
- 19,522 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Neoplasms
- Interventions
- LuCaS Decision Aid, NCI Website
- Behavioral
- Lead sponsor
- Jamie Studts
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Miami, Florida • Lexington, Kentucky
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma, Ependymoma Malignant, Ependymoma of Brain
- Interventions
- Specialized Tumor Board Treatment Plan, Combinations
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Months to 39 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 5 more
- Conditions
- Kartagener Syndrome, Cystic Fibrosis, Pseudohypoaldosteronism, Primary Ciliary Dyskinesia
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Denver, Colorado • Bethesda, Maryland + 3 more
- Conditions
- Endometrial Hyperplasia
- Interventions
- Ultrasound and Biopsy
- Procedure
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Breast Cancer, Tear, Breast Cancer Female
- Interventions
- Schirmer Strip
- Other
- Lead sponsor
- Namida Lab
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- Endometrial Cancer
- Interventions
- Sonohysterography
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Maternal Neoplasia
- Interventions
- NIPT
- Device
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-related Macular Degeneration
- Interventions
- VMS diary booklet, Standard of Care
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Endometrial Cancer, Gynecological Cancers
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 45 Years to 120 Years · Female only
- Enrollment
- 1,932 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota